Literature DB >> 21666443

Simvastatin in traumatic brain injury: effect on brain edema mechanisms.

Tiphaine Béziaud1, Xiao Ru Chen, Nelly El Shafey, Magalie Fréchou, Fei Teng, Bruno Palmier, Virginie Beray-Berthat, Mathieu Soustrat, Isabelle Margaill, Michel Plotkine, Catherine Marchand-Leroux, Valérie C Besson.   

Abstract

OBJECTIVES: Traumatic brain injury causes deleterious brain edema, leading to high mortality and morbidity. Brain edema exacerbates neurologic deficits and may be attributable to the breakdown of endothelial cell junction protein, leukocyte infiltration, and matrix metalloproteinase activation. These all contribute to loss of blood-brain barrier integrity. The pleiotropic effects of statins, hydroxymethylglutaryl-coenzyme A reductase inhibitors, may inhibit posttraumatic brain edema. We therefore investigated the effect of acute simvastatin on neurologic deficits, cerebral edema, and its origins.
DESIGN: Randomized laboratory animal study. SETTINGS: University-affiliated research laboratory.
SUBJECTS: Male Sprague-Dawley rats.
INTERVENTIONS: Rats were subjected to lateral fluid percussion traumatic brain injury. Our preliminary dose-effect study indicated that 37.5 mg/kg simvastatin, administered orally 1 hr and 6 hrs after traumatic brain injury, has the greatest anti-edematous effect. This dose was used to study its effects on brain edema and on its mechanisms.
MEASUREMENTS AND MAIN RESULTS: We first assessed the effects of simvastatin 24 hrs after traumatic brain injury on brain edema, brain claudin-5 expression, and the vascular endothelial-cadherin (pTyr731)/total vascular endothelial-cadherin ratio, matrix metalloproteinase-9 activity, intercellular adhesion molecule-1 expression, and polymorphonuclear neutrophil infiltration. We also evaluated blood-brain barrier permeability by measuring Evans blue and fluorescein sodium salt extravasation into the cerebral parenchyma. We then investigated whether simvastatin reduces neurologic deficits, edema, and blood-brain barrier permeability earlier than 24 hrs; these effects were evaluated 6 hrs after traumatic brain injury. The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Earlier, 6-hrs after traumatic brain injury, simvastatin reduced neurologic deficits, cerebral edema, and blood-brain barrier permeability.
CONCLUSIONS: Simvastatin could be a new therapy for reducing posttraumatic edema by preventing damage to tight junctions and neutrophil infiltration into the parenchyma, thus preserving blood-brain barrier integrity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666443     DOI: 10.1097/CCM.0b013e3182227e4a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

1.  Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin.

Authors:  Weiguo Chen; Rajesh Sharma; Alicia N Rizzo; Jessica H Siegler; Joe G N Garcia; Jeffrey R Jacobson
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

2.  Psychologic disorders and statin use: a propensity score-matched analysis.

Authors:  Ishak Mansi; Christopher R Frei; Mary J Pugh; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2013-04-26       Impact factor: 4.705

Review 3.  Strategies targeting endogenous neurogenic cell response to improve recovery following traumatic brain injury.

Authors:  Kaushal Patel; Dong Sun
Journal:  Brain Res       Date:  2016-02-08       Impact factor: 3.252

4.  Deletion of Nrf2 Exacerbates Oxidative Stress After Traumatic Brain Injury in Mice.

Authors:  Xin-Yu Lu; Han-Dong Wang; Jian-Guo Xu; Ke Ding; Tao Li
Journal:  Cell Mol Neurobiol       Date:  2015-03-03       Impact factor: 5.046

Review 5.  Treatment of traumatic brain injury with anti-inflammatory drugs.

Authors:  Peter J Bergold
Journal:  Exp Neurol       Date:  2015-06-23       Impact factor: 5.330

Review 6.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

7.  Platelet-Derived Growth Factor Receptor-β Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.

Authors:  Peng Yang; Jiang Wu; Liyan Miao; Anatol Manaenko; Nathanael Matei; Yang Zhang; Liang Xu; William J Pearce; Richard E Hartman; Andre Obenaus; John H Zhang; Feng Xu; Jiping Tang
Journal:  Crit Care Med       Date:  2016-06       Impact factor: 7.598

8.  Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users.

Authors:  Bilal Khokhar; Linda Simoni-Wastila; Julia F Slejko; Eleanor Perfetto; Min Zhan; Gordon S Smith
Journal:  J Head Trauma Rehabil       Date:  2018 Nov/Dec       Impact factor: 2.710

9.  Targeting Caveolin-1 and Claudin-5 with AY9944, Improve Blood-Brain Barrier Permeability; Computational Simulation and Experimental Study.

Authors:  Leila Gholami; Safura Jokar; Yousef Fatahi; Hedayat Samandari; Javad Hamzehalipour Almaki; Marjan Hosseini; Mohsen Parviz
Journal:  Cell Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.046

10.  JM-20 Treatment After Mild Traumatic Brain Injury Reduces Glial Cell Pro-inflammatory Signaling and Behavioral and Cognitive Deficits by Increasing Neurotrophin Expression.

Authors:  Andrezza Bond Vieira Furtado; Debora Farina Gonçalves; Diane Duarte Hartmann; Aline Alves Courtes; Gustavo Cassol; Yanier Nunez-Figueredo; Deivison Silva Argolo; Ravena Pereira do Nascimento; Silvia Lima Costa; Victor Diogenes Amaral da Silva; Luiz Fernando Freire Royes; Félix Alexandre Antunes Soares
Journal:  Mol Neurobiol       Date:  2021-06-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.